Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 10:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1753–1776 of 22,226 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: control 2 Clear all

Conditions: Parkinson's Disease
Interventions: Rotigotine, Placebo; Drug · Other
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 7
States / cities: Reseda, California • Ventura, California • St. Petersburg, Florida + 4 more

Conditions: Type 2 Diabetes Mellitus, Hyperglycemia
Interventions: Whey protein, Placebo group; Dietary Supplement
Lead sponsor: University of California, Davis; Other
Eligibility: 25 Years to 70 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Neoplasms, Head and Neck
Interventions: Lapatinib, Chemoradiation, Placebo; Drug · Radiation · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 688 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 5
States / cities: Springfield, Illinois • St Louis, Missouri • New York, New York + 2 more

Conditions: Cognition Disorders in Old Age, Mild Cognitive Impairment, Cognitive Decline
Interventions: Niagen, Placebo Comparator; Dietary Supplement
Lead sponsor: Steven E Arnold, MD; Other
Eligibility: 60 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Charlestown, Massachusetts

Conditions: Food Addiction
Interventions: Low UP (meals provided), Low UP (self-guided), Active Control; Other
Lead sponsor: University of Michigan; Other
Eligibility: 22 Years to 60 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Accidental Fall
Interventions: step training, treadmill training; Behavioral
Lead sponsor: Virginia Polytechnic Institute and State University; Other
Eligibility: 65 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Blacksburg, Virginia

Conditions: Depression, Depressive Disorder, Depressive Symptoms, Depressive Disorder, Major, Depressive Episode, Depression Severe
Interventions: TNX-601 ER, Placebo; Drug
Lead sponsor: Tonix Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 27
States / cities: Little Rock, Arkansas • Bellflower, California • Glendale, California + 24 more

Conditions: Message Exposure (Sequence: Regular Then Flavor), Message Exposure (Sequence: Flavor Then Regular), No Message Exposure (Control Condition)
Interventions: Exposure to Anti-Vaping Messages (generic themes then flavor-specific themes), Exposure to Anti-Vaping Messages (flavor-specific themes then generic themes), Exposure to Anti-Vaping Messages (no message exposure); Behavioral
Lead sponsor: University of Georgia; Other
Eligibility: 18 Years to 29 Years
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Athens, Georgia

Conditions: Bleeding, Clot Blood
Interventions: Aspirin, Warfarin; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Chicago, Illinois • New York, New York • Houston, Texas

Conditions: Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions: Celecoxib; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 875 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 67
States / cities: Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 58 more

Conditions: Type 2 Diabetes
Interventions: Continuous Glucose Monitoring Academy, Standard Education; Behavioral
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 8 Years to 21 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cardiovascular Disease
Interventions: bococizumab (PF-04950615), Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 16,784 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 545
States / cities: Athens, Alabama • Birmingham, Alabama • Fort Payne, Alabama + 339 more

Conditions: Blood Loss, Surgical, Postoperative Hemorrhage
Interventions: Trasylol (Aprotinin, BAYA0128), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 18
States / cities: Los Angeles, California • Denver, Colorado • Miami, Florida + 14 more

Conditions: Healthy
Interventions: fesoterodine fumarate, placebo, solifenacin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Hyponatremia, Inappropriate ADH Syndrome
Interventions: Satavaptan, placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Pediatric Obesity, Sedentary Behavior
Interventions: Garden installation; Other
Lead sponsor: North Carolina State University; Other
Eligibility: 42 Months to 6 Years
Enrollment: 286 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 15
States / cities: Cary, North Carolina • Fuquay-Varina, North Carolina • Knightdale, North Carolina + 2 more

Conditions: Myalgia, Hypercholesterolemia, Hyperlipidemia
Interventions: PPD10558, Atorvastatin, Placebo; Drug
Lead sponsor: Furiex Pharmaceuticals, Inc; Industry
Eligibility: 40 Years and older
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 67
States / cities: Anniston, Alabama • Phoenix, Arizona • Huntington Park, California + 60 more

Conditions: Sleep, Sleep Quality, Sleepiness, Daytime, Technology
Interventions: Accurate Sleep Data Feedback, Inflated Sleep Data Feedback, Deflated Sleep Data Feedback, Accurate Sleep Data Feedback + Sleep-related Educational Information; Behavioral
Lead sponsor: NextSense, Inc.; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hepatitis C, Chronic
Interventions: GS-5885, GS-9451, peginterferon alfa-2a, ribavirin tablet, GS-9451 Placebo; Drug · Biological
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 351 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 21
States / cities: Tucson, Arizona • Beverly Hills, California • Coronado, California + 17 more

Conditions: Breast Cancer
Interventions: Persona: Primary care doctor, Persona: Breast cancer survivor, Communication Style: Direct, Communication Style: Indirect; Other
Lead sponsor: University of Washington; Other
Eligibility: 40 Years to 74 Years · Female only
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Healthy Volunteers
Interventions: AdCOVID, Placebo; Biological · Other
Lead sponsor: Altimmune, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 6
States / cities: Hialeah, Florida • Melbourne, Florida • Peoria, Illinois + 3 more

Conditions: Peripheral Neuropathy
Interventions: Acupuncture; Other
Lead sponsor: Prisma Health-Upstate; Other
Eligibility: 18 Years and older · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Greenville, South Carolina

Conditions: Coronavirus Disease 2019 COVID-19
Interventions: TJ003234, Placebo; Drug
Lead sponsor: I-Mab Biopharma US Limited; Industry
Eligibility: 18 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 14
States / cities: Little Rock, Arkansas • Sylmar, California • Washington D.C., District of Columbia + 10 more

Conditions: Headache
Interventions: Not listed
Lead sponsor: Planned Parenthood League of Massachusetts; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 171 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Randomized Evaluation of the 24-Hour Coverage: Efficacy of Rotigotine

Can Whey Protein Improve Glycemic Control in Type 2 Diabetes?

Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery

Crossover Trial for Nicotinamide Riboside in Subjective Cognitive Decline and Mild Cognitive Impairment

Ultra Crave: An Investigation of Ultra-Processed Food

Effects of Task-Specific Step Training on Reactive Balance

Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)

Neuroimaging Approaches to Improve Prediction of Smoking Initiation and Nicotine Escalation in Young Adult ENDS Users

Aspirin and Hemocompatibility Events in Chronic Advanced Heart Failure Patients With Assist Device

Study Of "Continuous Use" Of Celecoxib Vs. "Usual or Intermittent Use"

Type 2 Continuous Glucose Monitoring Academy

The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

Efficacy and Safety of Aprotinin on Transfusion Requirements in Patients Undergoing Radical or Total Cystectomy

Multiple Dose Study To Investigate The Effects Of Fesoterodine And Solifenacin On Gastrointestinal Transit

A Phase III Study Evaluating the Efficacy and Safety of Satavaptan Versus Placebo in Patients With Dilutional Hyponatremia

Childcare Outdoor Learning Environments as Active Food Systems

Study of the Safety and Tolerability Associated With PPD10558 Versus Atorvastatin in Patients Previously Intolerant to Statins Due to Statin-associated Myalgia (SAM)

Nextsense Brain-sensing Buds Study

GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus

Design of Chatbot Persona for Breast Cancer Screening Outreach Among Black Women

Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study)

Evaluating the Effects of Acupuncture in the Treatment of Taxane Induces Peripheral Neuropathy

Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)

Boston Migraine and Contraception Study